About EBSA06 Conference - Lyon
EBSA06 Conference - Lyon
“National and Global Disease Outbreaks / Living with Bioterrorism”
Programme
THURSDAY, 15 MAY 2003
| Registration | 08.00-09.00 |
| President's welcome | 09.00-09.10 |
|
SESSION 1: |
|
| Introduction and Chair Dr. Barbara Johnson , President ABSA, Center for Biosecurity Strategy, Science Applications International Corporation, USA |
09.10-09.20 |
|
Biosafety Management: University Perspective Simon Caidan, National Institute for Medical Research, London, UK |
09.20-09.50 |
|
Biosafety Management: Industry Perspective Dr. David Revitt, Research HSE, Novartis Research Centre, Horsham, UK |
09.50-10.20 |
| Discussion | 10.20-10.35 |
| Break | 10.35-11.00 |
| Session 1: Biosafety Management - Concurrent Breakout Sessions |
|
| Session 1 A: Training Chair: Dr. Kerri Mack, DSTL, Porton Down, UK This session on training will be based on the active participation of the attendees in sharing their experiences of different methods of biosafety training and problems encountered. The participants will be encouraged to think about why some methods are more successful than others, to brainstorm new ideas to take back to their organisations and to recognise common pitfalls. |
11.00-12.30 |
| Session 1 B: Dealing with a Spillage Chair: John Newbold, Health and Safety Executive, UKMeeting Any accidental release of hazardous biological agents requires appropriate action to be taken based on an assessment of the risk. The development of suitable contingency plans can help ensure that the impact on human health or to the environment is minimised. This open forum will explore different types of accidents/spillages, particularly at containment level 3, using examples to help stimulate discussion and provide guidance on practical solutions. Scene setting will be provided by co-ordinators for participants to explore such important topics as: assessment of risk, emergency plans, disinfection/fumigation (when & how), training needs and any legislative requirements. |
11.00-12.30 |
|
Session 1 C: This session will adopt a workshop type format, the intention being for participants to make an active contribution, raising issues and seeking problem resolution. To stimulate participation the coordinator will set the scene describing requirements in general terms for a broad spectrum of biohazards and giving his interpretation of how appropriate standards are met. Participants will be encouraged to describe their approaches with discussion directed at determining best-practice and advantages and shortcomings of differing procedures |
11.00-12.30 |
| Lunch | 12.30-13.30 |
| SESSION 2: General Laboratory Design, Construction and Operation Chair: Dr. Philippe Stroot, Glaxo SmithKline Biologicals, Belgium |
13.30-15.00 |
|
Containment Design Solutions: a User's Perspective |
13.30-14.00 |
|
Learning Flexible design through experience |
14.00-14.30 |
| Designing to be Commissioned Jim Orzechowski, Smith Carter Architects and Engineers, Winnipeg, Canada | 14.30-15.00 |
| Break | 15.00-15.30 |
| Free Communications Chair: Dr. Frank Verbeeck, Bristol-Myers Squibb, EBSA President |
15.30-16.10 |
| 'In culture' real-time PCR, an efficient tool for monitoring contaminations in laboratories Dr. Claudia Bagutti, Kantonales Laboratorium, Biological and Chemical Safety Administration, Basel, Switzerland |
15.30-15.50 |
| Accidents and biological risk in Italian hospitals Dr. Dimitri Sossai, Director Prevention and Protection Service, San Martino Hospital, Genova, Italy |
15.50-16.10 |
|
"Chris Collins Lecture" Is our Focus to be more Biosafety or Biosecurity in the Era of Bio-Terrorism? |
16.10-17.00 |
| Annual General Meeting, for EBSA Members only | 17.00-18.00 |
| Conference Reception and Dinner, Visit to Lyon by boat and local dinner Meeting Place: Lobby Novotel Gerland |
19.30 |
FRIDAY, 16 MAY 2003
| Session 3: Three Concurrent sessions on Facility Design, Construction and Operations |
09.00-10.30 |
| Session 3A: Research Animals, Chair: Dr. Kathrin Bernard, Institute for Virology and Immunoprophylaxis, Mittelhausern, Switzerland |
|
| Principles of containment of veterinary pathogens associatedwith animals Dr. Philippe Jeannin, DVM, MSc. Director EU Clinical Research and Development, MERIAL |
09.00-09.30 |
| Primary Animal Containment Systems Mr. Simon Parks, CAMR, Porton Down, UK | 09.30-10.00 |
| Animal Biosafety Level 3 Management Dr. Christian Griot, Institute for Virology and Immunoprophylaxis, Mittelhausern, Switzerland |
10.00-10.30 |
| Session 3B: Large Scale Chair: Dr. Harald Haymerle, Risk Engineering, Zurich Insurance, Vienna, Austria |
|
| Bioprocess Equipment Design Criteria: Process and Operator Protection Dr. Otto Doblhoff-Dier, Igeneon, Vienna |
09.00-09.30 |
| GMP and Biosafety in Biological (vaccine) Manufacturing operations : Interfaces and Overlaps Marc Guillaud, DVM, Head of Corporate Quality/Biosafety Operations, Merial, Lyon, France |
09.30-10.00 |
| Viral Vaccine Manufacturing Unit Design Jean-Marc Jalby, Project Leader, Aventis Pasteur, Lyon, France | 10.00-10.30 |
| Session 3C: Plants / Insects / Arthropod Vectors Chair: Esmeralda Prat, Bayer Crop Science, Belgium |
|
| Containment of plant pests under Directive 95/44/EC in Great Britain Roger Tuppen, Export Advice and Import Licensing, Central Science Laboratory, York, UK |
09.00-09.30 |
| Working Biosafely with Bacteria, Fungi, Viruses and Insects in Greenhouses Dr. Benedictus J.M. Verduin, Laboratory of Virology, Wageningen University , The Netherlands |
09.30-10.00 |
| Facility and Management Practices for Infected Mosquitos as Vector of Plasmodium Falciparum Dr. Kai Matuschewski, Institute for Infection Control, Parasitology, Heidelberg, Germany |
10.00-10.30 |
| Break | 10.30-11.00 |
| Session 4: Clinical / Hospital Transport and Operations Chair: Dr. Bradford Kay, Coordinator Laboratory Capacity Development, WHO/OMS CSR/Lyon Office |
11.00-12.15 |
| Overview of Changes in Transport Regulations Dr. Nicoletta Previsani, WHO, Geneva |
11.00-11.25 |
| Protecting healthcare workers in the EU - Eucomed action on eliminating sharps injuries Albert Scius, European Director Advance Protection Technology, Becton Dickinson, France |
11.25-12.00 |
| Session 5: Occupational Health and Laboratory Ergonomics Chair: Dr. Juergen Mertsching, Medical School Hannover, Germany |
12.00-13.00 |
| Management of Biological Risks in a Pharmaceutical Company: Interaction between the Occupational Doctor and the Biosafety Officer Dr. LucBuelens, Glaxo Smithkline Biologicals, Rixensart, Belgium |
12.00-12.30 |
| Laboratory Ergonomics Dr. Ian Randle, Hu-Tech, UK |
12.30-13.00 |
| Closure by the EBSA president 2003-2004, Dr. Kathrin Bernard | 13.00 |
| Lunch | 13.00-14.00 |